UPDATE – Rain Oncology to Participate in the 2023 Guggenheim Healthcare Talks Oncology Day Conference
NEWARK, Calif., Jan. 31, 2023 (GLOBE NEWSWIRE) -- In a release issued earlier today by Rain Oncology (NASDAQ: RAIN), the company is updating their presentation date and time to Thursday, February 9,
Rain Therapeutics Price Target Announced at $21.00/Share by Roth Capital
Rain Therapeutics Price Target Announced at $21.00/Share by Roth Capital
Roth Capital Reinstates Buy on Rain Oncology, Announces $21 Price Target
Roth Capital analyst Kumaraguru Raja reinstates Rain Oncology (NASDAQ:RAIN) with a Buy and announces $21 price target.
Rain Oncology to Participate in the 2023 Guggenheim Healthcare Talks Oncology Day Conference
NEWARK, Calif., Jan. 31, 2023 (GLOBE NEWSWIRE) -- Rain Oncology Inc. (NasdaqGS: RAIN), ("Rain"), a late-stage company developing precision oncology therapeutics with its lead product candidate, mila
Rain Oncology Resumed With a Buy at Roth Capital
Citi Opens 'Upside 90-Day Catalyst Watch' on Rain Oncology
Rain Therapeutics Price Target Announced at $18.00/Share by Mizuho
Rain Therapeutics Initiated at Buy by Mizuho
Rain Oncology Announces Publication of Phase 1 Data of Milademetan
Mizuho Initiates Coverage On Rain Oncology With Buy Rating, Announces Price Target of $18
Mizuho analyst Graig Suvannavejh initiates coverage on Rain Oncology with a Buy rating and announces Price Target of $18.
Loading...
No Stock Yet